US access in jeopardy despite rising savings

Access to medicines in the US is “in jeopardy”, the country’s Association for Accessible Medicines (AAM) has warned in its latest report, despite generic drugs enabling the US to realise savings of US$265.1 billion in 2017, according to Iqvia data.